score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.1812	149.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600M	0.1769	147.0	0.0	0.0		Investigate Actionability - High	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - High	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600M (Missense)	1.0	MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Investigate Actionability - High	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Ipilimumab	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498												0				 mutations per Mb		MEL-IPI_Pat147		
Investigate Actionability - Low			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.0714	112.0	0.0	0.0														Investigate Actionability - Low	1.0	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324	0				CTNNB1 p.S33P (Missense)		MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2027K	0.0926	216.0	0.0	0.0																			0				ROS1 p.E2027K (Missense)		MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Y800N	0.11800000000000001	305.0	0.0	0.0																			0				ROS1 p.Y800N (Missense)		MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G799E	0.1155	303.0	0.0	0.0																			0				ROS1 p.G799E (Missense)		MEL-IPI_Pat147	MEL-IPI_Pat147-Tumor-SM-7A158	MEL-IPI_Pat147-Normal-SM-5VWI7
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat147		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.768																							0				COSMIC Signature 7 (77%)		MEL-IPI_Pat147		
